Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

Authors:

Abstract
No abstract available
Funding Information
  • Celgene
  • Takeda Pharmaceutical Company
  • Janssen Research and Development
  • Janssen Pharmaceutica

This publication has 19 references indexed in Scilit: